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Abstract
Background
Psoriasis is a long-term immune-mediated inflammatory disorder mainly, but not only,
affecting skin, and is associated with significant medical and psychological morbidity. Evi-
dence suggests that sleep is disrupted in psoriasis, however high quality empirical evidence
is lacking. Given the importance of sleep for health, characterisation of sleep disruption in
psoriasis is an important goal. We therefore conducted a systematic review of the sleep-
psoriasis literature.
Methods
Searches were conducted in Pubmed, SCOPUS andWeb of Science from inception to May
2016. Studies were compared against inclusion/exclusion criteria and underwent a quality
evaluation. Given the heterogeneity of studies, we conducted a narrative synthesis of the
findings.
Results
Searches revealed 32 studies which met our predetermined inclusion/exclusion criteria.
Whilst 93.7% of studies reported sleep disruption in this population, ranging from 0.05% to
85.4%, many had important methodological shortcomings. Over half of all quantitative stud-
ies (54.8%; 17/31) relied on non-validated measures, contributing to heterogeneity in study
findings. In those that employed valid measures, assessing sleep was often not the primary
objective. We frequently found the absence of adequate sample size calculations and poor
statistical reporting.
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Conclusion
This review showed that in psoriasis, reported sleep rates of sleep disturbance varied sub-
stantially. Most studies lacked a hypothesis driven research question and/or failed to use
validated measures of sleep. We were unable to draw firm conclusions about the precise
prevalence and nature of sleep disturbance within the psoriasis population. We offer sug-
gestions to help advance understanding of sleep disturbance in psoriasis.
Introduction
Psoriasis is a long-term, immune mediated inflammatory skin disorder, characterised by scaly
plaques on knees, elbows and scalp, but any skin surface may be affected [1]. Population-based
cohort studies indicate that psoriasis is associated with other systemic inflammatory condi-
tions, including: psoriatic arthritis (PsA) [2]; inflammatory bowel disease [3]; cardiovascular
disease (CVD) [4]; and diabetes [5].
Contemporary evidence suggests that sleep is important for daytime functioning and health,
[6–8] subserving optimal physiological [9] and psychological functioning [10–13]. Moreover,
disturbed sleep may causally drive disease processes. For example, persistent sleep disturbance
is a risk factor for the future development of diabetes [14], CVD [15, 16], hypertension [17,18],
and depression [19–22]. Several studies [23–38], including four reviews, have examined sleep
domains in psoriasis populations. One review evaluated factors linked to sleep disturbance in
psoriasis, concluding that mood, obstructive sleep apnoea (OSA), itch and pain as possible
sources of sleep disturbance [29]. Another review provided an overview of the sleep and der-
matology literature with a focus on the role of itch, suggesting skin temperature, circadian
rhythm and psychological factors, such as depression, influenced itch, which in turn disrupted
sleep [30]. Similarly, a further review assessed the associations between sleep disorders and the
broad category of skin disorders [31]. More recently, Gupta et al. conducted a systematic
review of psoriasis and sleep disorders and found an increased prevalence of OSA and restless
leg but inconclusive evidence of increased insomnia risk [32]. Whilst these reviews provide
some insight into the nature and predictors of sleep in psoriasis the majority are narrative and
none critically examine the measures used to assess sleep nor do they assess the quality of cur-
rent research. Additionally the most recent review [32] only included papers where a sleep dis-
order diagnosis was made, thus excluding studies where sleep was assessed without a diagnosis,
potentially missing research where sleep was assessed but no diagnosis was made. Accordingly,
a more rigorous and nuanced appraisal of the sleep-psoriasis literature is required. We present
a systematic review focusing on (1) the evidence for sleep disturbance in psoriasis and (2) the
quality of measures and methodology employed to assess sleep in patients with psoriasis. We
conclude by outlining a research agenda aimed at advancing understanding of sleep distur-
bance in the context of psoriasis.
Method
Search criteria
PubMed, SCOPUS and Web of Science databases were searched from inception to May 2016.
We used the PICOS framework (Population, Interventions, Comparators/Control, Outcomes,
Study design) [33] however the intervention category could not be applied due to poor report-
ing and/or too much variation in study design. In order to increase the sensitivity of the search,
search terms were kept broad and were combined using ‘AND’ plus wildcard operators () and
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MeSH terms (Table 1). Studies were assessed against inclusion/exclusion criteria determined
by an expert group of reviewers (Table 2). Reference lists of eligible studies were forward and
backward searched for completeness. Reviews were included to identify additional studies that
were not identified via database searches.
Data extraction
Data extracted from studies included: authors, title, year, study aim(s), journal, study design,
type of psoriasis, sample size, measure of sleep used and findings relating to sleep (Tables 3–5).
Quality Evaluation
We adapted a standard quality scoring tool [34] for quantitative and qualitative study designs
to include information about the quality of the sleep measure used, details of potential con-
founding variables and the sleep findings reported by each paper. Members of the review team
(ALH, SB, CB, AC) tested the quality tool on a sample of four papers. The first author then
reviewed all papers, discussing any problems with the fourth and sixth authors with amend-
ments discussed and agreed upon during subsequent meetings until there was full agreement
on the domains included in the tool. Subsequently ten randomly selected papers were coded by
the third author (SB) independently with these scores compared to those of the first author
(ALH). Disagreement in scores was found for one domain which was resolved following dis-
cussion with the rest of the team resulting in 100% agreement.
Fifteen domains were used for quantitative papers and seven for qualitative papers (supple-
mentary data). Each quality evaluation domain had specific criteria that had to be fulfilled in
order to obtain a score from 0 to 2. A standardised rating scale was used to score each item
thus: a score of 2 indicates that criteria had been fulfilled, a score of 1 indicates partial fulfill-
ment, and a score of 0 indicates no fulfillment of the criteria. Quantitative studies, depending
on their design could score a maximum score of 40, whereas qualitative studies could score a
maximum of 22 points.
Table 1. Search terms used across databases.
1. Sleep /OR sleep disruption /OR sleep disturbance /OR sleep fragmentation
2. Psoriasis/ OR chronic plaque psoriasis/ OR psori*
3. Circadian*/ OR circadian rhythm
4. 1 OR 3
5. 4 AND 2
doi:10.1371/journal.pone.0157843.t001
Table 2. Inclusion criteria for studies.
Inclusion Criteria Exclusion
Criteria
1. Partial or whole psoriasis sample (including any subtype of psoriasis or psoriatic
arthritis)
1. Not peer
reviewed
2. Sleep was measured either directly using a valid measure of sleep, unvalid
measure of sleep or by-proxy via another measure
2. Animal studies
3. Any study design
4. Any age group
5. Published in English
6. Accessible in full text
doi:10.1371/journal.pone.0157843.t002
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Table 4. Information (i.e. aim, study design, primary focus of the study, measure of sleep used, sample, pertinent results relating to sleep) and
quality scores for each study using an unvalidated measure of sleep included in the review.
Type of
measure of
sleep
Study Aim Study
Design
Primary
focus
on sleep
Measure of
Sleep
Participants Results
pertaining to
sleep
Quality
Score
Quality
Percentage
Quality
Decision
HRQoL
(unvalidated
subjective)
Takahasi
et al., 2013
Investigated the
effect of various
treatments on
QoL and mental
health of
psoriasis patients
Cross-
sectional
study
No GHQ-30 199 patients
with psoriasis
vulgaris
Biologics, other
treatments and
topical treatments
all resulted in
signiﬁcant
reductions in
sleep disturbance
from pre-to-post
treatment, with
biologics having
the greatest effect
(P < 0.05)
21/32 65.6 fair
HRQoL/
Medical
Record
(unvalidated
subjective)
Sanchez-
Carazo
et al., 2014
Analyse the
clinical proﬁle of
patients with
moderate-to-
severe psoriasis
with regards to
comorbid
conditions and to
establish its
correlation with
QoL
Cross-
sectional
survey
No Medical history/
SF-36
1022 patients
with psoriasis
Moderate-severe
psoriasis patients
who possessed a
diagnosis of a
sleep disorder
(12.2%) had
signiﬁcantly lower
SF-36 scores
(P < 0.05)
26/30 86.7 good
HRQoL
(unvalidated
subjective)
Kim et al.,
2013
Examine the
relative effects of
psoriasis and
obesity on
Chronic QoL by
analysing the
physical and
psychological
burden of the
disease that
accumulate
across the
lifespan
Cross-
sectional
survey
No Modiﬁed DLQI
(Chronic QoL)
to include
questions about
social and
psychological
problems due to
psoriasis
114 patients
with psoriasis
Sleep problems
were signiﬁcant
across the lifetime
(p<0.05) for those
with higher BMI.
24/30 80 good
HRQoL
(unvalidated
subjective)
Oostveen
et al., 2012
Longitudinal
assessment of
QoL in juvenile
psoriasis
Longitudinal
study
No CDLQI 125 children
with psoriasis
Sleep disturbance
as measured by
CDLQI reduced
signiﬁcantly from
initial visit to
follow up across
all treatments
(P < 0.05), with it
having the
greatest
improvement
along with itch.
25/30 83.3 good
Pain
questionnaire
(unvalidated
subjective)
Ljosaa
et al., 2010
Describe the
prevalence of
skin pain and
discomfort in
psoriasis
patients, whether
skin pain/
discomfort
differed on
demographic and
clinical levels and
to explore
associated
symptom
characteristics
Cross-
sectional
study
No BPI (30) 139 patients
with psoriasis
Sleep was the
most severely
disrupted function
(P < 0.05)
reported by 74/
139 participants.
27/30 90 good
(Continued)
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Table 4. (Continued)
Type of
measure of
sleep
Study Aim Study
Design
Primary
focus
on sleep
Measure of
Sleep
Participants Results
pertaining to
sleep
Quality
Score
Quality
Percentage
Quality
Decision
General
Health
(unvalidated
subjective)
Sharma
et al., 2001
Evaluate
psychiatric
morbidity
associated with
psoriasis and
vitiligo
Case-control
study
No GHQ-H 30 patients
with psoriasis
or vitiligo
Sleep disturbance
was the most
common
complaint,
reported by
56.7% of
psoriasis patients
23/32 71.9 fair
Pain
questionnaire
(unvalidated
subjective)
Yosipovitch
et al., 2000
Assess the
prevalence of itch
in extensive
psoriasis in an
outpatient clinic
and to assess its
clinical pattern
Cross-
sectional
study
No Questionnaire
based on the
McGill Pain
Questionnaire
101 patients
with psoriasis
69% of patients
report that itch
results in difﬁculty
falling asleep,
with 66% being
woken up as a
result of itch
25/30 83.3 good
Clinical
Interview
Nyunt et al.,
2013
Determine the
impact of
psoriasis on
HRQoL, examine
the factors
associated with
HRQoL
impairment and
determine
predictive factors
of severe impact
of psoriasis on
HRQoL
Cross-
sectional
study
No Clinical
interview
223 patients
with psoriasis
Sleep disturbance
as reported via
clinical interview
was signiﬁcantly
associated with
severe reductions
in DLQI score
(P < 0.05)
25/30 83.3 good
Medical
records
Tsai et al.,
2011
Describe the
epidemiology of
psoriasis and the
prevalence of
comorbidities in
Taiwanese
psoriasis patients
Cross-
sectional
study
No Medical
Records
51,800
patients with
psoriasis
Sleep disorders
had a signiﬁcantly
increased
prevalence ratio
in psoriasis
patients (3.89
[2.26, 6.71)
(p<0.05.)
23/38 82.14 good
Medical
records
Egeberg
et al., 2016
To examine the
bidirectional
impact of
psoriasis and
sleep apnoea
Cohort study Yes Medical
Records
66,523
patients with
psoriasis
Psoriasis was
associated with
elevated risk of
obstructive sleep
apnoea even
when adjusting
for age, sex,
alcohol,
comorbidities and
socioeconomic
status. (mild
psoriasis: IRR:
1.30, 95% CI:
1.17–1.44, severe
psoriasis: IRR:
1.65, 95%
CI:1.23–2.22)
26/30 86.7 good
Medical
records
Chiu et al.,
2016
Investigate the
association
between
cardiovascular
risk and sleep
disorders in
psoriasis
Cohort study Yes Medical
Records
99,628
patients with
psoriasis
Sleep disorders
were signiﬁcantly
associated with
increased
cardiovascular
risk (aHR: 1.25,
95% CI:1.22–
1.38) and stroke
(aHR: 1.24, 95%
CI:1.1–1.33)
23/26 88.5 good
(Continued)
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Table 4. (Continued)
Type of
measure of
sleep
Study Aim Study
Design
Primary
focus
on sleep
Measure of
Sleep
Participants Results
pertaining to
sleep
Quality
Score
Quality
Percentage
Quality
Decision
Unvalidated
individual
question
Dufﬁn et al.,
2009
Determine what
aspects of
psoriasis and
psoriatic arthritis
are predictive of
sleep disturbance
using the
National
Psoriasis
Foundation
patient surveys
Cross-
sectional
study
Yes Individual
question ('In a
typical month
how many days
did your
disease
interfere with
your sleeping?')
420
individuals
with psoriasis
Psoriatic arthritis
and itch were
signiﬁcant
predictors of
sleep disturbance
(P < 0.05).
21/30 70 fair
proxy HRQoL
(unvalidated
subjective)
Hu et al.,
2010
Pilot a WTP
instrument and
evaluate its
feasibility in
measuring
HRQoL domains
within PsA
Cross-
sectional
study
No Willingness-to-
pay paradigm
59 patients
with psoriasis
and PsA
The highest
median amount of
money individuals
were willing to
pay for a cure
was applied to
sleep ($10,000)
23/28 82.1 good
proxy HRQoL
(unvalidated
subjective)
Delﬁno
et al., 2008
Pilot a WTP
instrument and
evaluate its
feasibility in
measuring
HRQoL domains
within Psoriasis
and to identify
areas of HRQoL
most severely
affected by
psoriasis
Cross-
sectional
study
No Willingness-to-
pay paradigm
40 patients
with psoriasis
Sleep was
allocated the
lowest median
amount of money
by patients
($625), but was
reported by 22/40
participants as
being present.
22/28 78.6 fair
Itch
questionnaire
(unvalidated
subjective)
Amatya
et al., 2008
Characterize
pruritus and its
aggravating and
relieving factors
and to assess the
effect of
treatment and the
impact of itch on
QoL in psoriasis
Cross-
sectional
study
No Pruritus
questionnaire
with one sleep
item
80 patients
with psoriasis
35% of individuals
report itch as
interfering with
their sleep, and
65% report that
good sleep
improves itch
23/30 76.7 fair
Unvalidated
sleep
questionnaire
Gupta &
Gupta.,
1989
Comparison of
the
dermatological
and psychosocial
factors of two
psoriasis groups,
both of whom
report severe itch
during
wakefulness with
and without
frequent
nocturnal
awakenings from
sleep
Case-control
study
Yes Sleep
questionnaire
assessing
discomfort
during sleep
79 patients
with psoriasis
(46 with
nocturnal
awakenings
and 33
without)
W group reported
greater discomfort
due to shedding
(P < 0.05); heat
intolerance
(P < 0.05); cold
intolerance
(P < 0.05) and
jerking of limbs
during sleep
(P < 0.05), and
increased
presence of
depression than
the without
awakenings
group. No
signiﬁcant
differences
relating to
pruritus.
22/30 73.3 Fair
(Continued)
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Each paper's total quality score was then standardised as a percentage, obtained by dividing
the study’s score by the total points available. Quality appraisal thresholds determined by the
team were then applied to each study based upon its percentage score (good:80%; fair:61–
79%; and poor:60%).
Results
We identified 337 original papers. Abstracts were screened for eligibility and 42 full papers
were obtained and scrutinised (Fig 1). In total, 32 papers were included in the final review.
Thirty-one studies employed quantitative designs, and one study used a qualitative framework.
We structure our review findings under the following category headings: study quality; sleep
methodology and prevalence of sleep disruption; and factors associated with sleep disturbance.
Study Quality
Fewer than half of all studies (15/32; 46.9%) were rated as good quality (i.e. scoring 80%),
over fair (15/32;46.9%) (scoring 61–79%), and the remainder (2/32; 6.25%) as poor
Table 4. (Continued)
Type of
measure of
sleep
Study Aim Study
Design
Primary
focus
on sleep
Measure of
Sleep
Participants Results
pertaining to
sleep
Quality
Score
Quality
Percentage
Quality
Decision
Unvalidated
sleep question
Krueger
et al., 2001
Assess patient's
views on the
impact of
psoriasis on their
life and emotional
wellbeing, along
with obtaining
their views and
satisfaction of
current
treatments
available
Cross-
sectional
survey
No Single question
asking what
activities of
daily living are
impacted by
psoriasis
17,488 Sleep was the
second most
disrupted activity
of daily living,
indicated by 20%
of 18–34 year
olds, 22% of 35–
54 year olds and
22% of those
>55.
20/28 71.4 Fair
BMI—Body Mass Index, BPI (30)–Brief Pain Inventory, (C)DLQI—(Children’s) Dermatology Life Quality Index, GHQ-30 –General Health Questionnaire
(30) HRQoL/QoL—Health related quality of life/Quality of Life, SF-36 –Short Form 36 Health Survey
doi:10.1371/journal.pone.0157843.t004
Table 5. Information (i.e. aim, study design, primary focus of the study, measure of sleep used, sample, pertinent results relating to sleep) and
quality scores for the qualitative included in the review.
Type of
measure
of sleep
Study Aim Study
Design
Primary
focus on
sleep
Measure
of Sleep
Participants Results
pertaining to
sleep
Quality
Score
Quality
Percentage
Quality
Decision
Focus
groups
and
interviews
Globe
et al.,
2009
Develop a
disease model
of psoriasis to
identify the
most important
domains to
psoriasis
patients
through
physician
interviews and
patient focus
groups
Qualitative
study
No Focus
group
31 patients with
psoriasis and 5
dermatologists
Patients
reported that
they
experienced
difﬁculty falling
asleep, waking
up, having non
restorative sleep
and sleeping
less
19/22 86.4 good
doi:10.1371/journal.pone.0157843.t005
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(scoring 60%) (Tables 3–5). Overall quality scores were fair (mean % = 76.9), with a number
of methodological limitations identified across studies: 27 studies failed to perform sample size
calculations, 17 had inappropriately small or large sample sizes, 7 studies did not provide
demographic data, 2 studies failed to report any data on central tendency or variability, and 5
studies reported this data for only one time point and 14 studies failed to control for confound-
ing variables (S1 Table). Of the 14 studies using valid measures of sleep, the majority (9) scored
in fair (scoring 61–79%), and poor (2) categories (scoring 60%) and only 3 were rated as
good (scoring80%).
Fig 1. PRISMA Flow diagram outlining the systematic review process.
doi:10.1371/journal.pone.0157843.g001
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Measurement and prevalence of sleep disturbance
Studies used a range of sleep measures but only in 14 of 31 (45.2%) had these been validated.
Five studies used polysomnography (PSG), and focused on OSA [26,27,35,36] or itch [37],
with one of these also using the Functional Outcomes of Sleep Questionnaire [26]. Four used
the Pittsburgh Sleep Quality Index (PSQI) [23,24,38,39], one of which was conducted on a PsA
sample [39] and one study used a condensed version of the PSQI [40]. One study used the
Insomnia Severity Index (ISI) [23] while a further four studies used other validated self-report
measures specifically, the General Sleep Disturbance Scale [41] and the Medical Outcomes
Study Sleep Scale (MOS-SS) [28,42,43]. One study was qualitative, evaluating the impact of
pruritus using interviews with physicians alongside patient focus groups [44].
The remaining 17 (54.8%) quantitative studies used non-validated sleep measures. Six stud-
ies used broad measures of health and functioning, which incorporated sleep items, such as
measures health-related quality of life (HRQoL) (General Health Questionnaire, modified Der-
matology Life Quality Index, Children’s Dermatology Life Quality Index, General Health Ques-
tionnaire Hindi) or other general health-related questionnaires (Brief Pain Inventory, McGill
Pain Questionnaire) [45–50]. Four studies used non-validated questionnaires [25,51–53] three
of which contained a single item pertaining to sleep disturbance [25,52,53] (e.g "in a typical
month, how many days did your disease interfere with sleeping?”) [25]. Four studies solely
used medical records [54,55,56,57], and another used a clinical diagnostic interview with a
sleep disorder diagnosis [58]. In two validation studies HRQoL was assessed using a willing-
ness-to-pay paradigm, where participants were asked to indicate how much money they would
allocate to relieve themselves of a particular symptom [59,60]. Interestingly, in one of the stud-
ies using a PsA sample, sleep was allocated the highest median amount of money ($10,000)
[60], whereas in the other study, with a psoriasis sample, sleep was the lowest ranked issue
($625) [59].
Of all studies reviewed, 11 (34.4%) had an a priori aim to assess sleep, however, only three
(9.4%) had the primary objective of assessing sleep quality and quantifying sleep disturbance in
psoriasis [23,24,37]. The other studies were not primarily focused on general sleep in psoriasis.
Two studies investigated associations between PsA and sleep [25,39] while four studies assessed
the link between OSA and psoriasis [26,27,35,36]. The remaining two studies measured the
influence of itch on psoriasis [37,51], one of which used a mixed dermatological sample [37]
with just 1 of 15 participants (6.67%) having psoriasis. The former [51] used a questionnaire
and the latter [37] used PSG to assess sleep. One study aimed to assess the links between sleep
disorders in psoriasis and cardiovascular risk [56].
Thirty (93.7%) of 32 studies, including one qualitative study, observed sleep disturbance.
However, in studies where sleep was measured prospectively, values varied from 0.05% to
87.5% (Table 6). Two papers reported no sleep problems relative to healthy controls [24,59]. In
one of these studies, whilst sleep disturbance was reported by the majority (55%) of partici-
pants, relative to other domains of life, sleep disturbance was the least bothersome [59].
In contrast, another study reported sleep as being the second-most disrupted domain as a
consequence of psoriasis, across young, middle aged and older-aged respondents; indicated by
20%, 22% and 22% respectively [53]. Sleep quality was worse in psoriasis patients (8.8±4.4 vs.
6.3±4.4) [23] and PsA patients (9.70±3.9 vs. 4.05±1.85) [39] relative to healthy controls in two
out of three studies using PSQI with the third paper showing no difference between psoriasis
patients and controls (5.56 vs. 5.13) [46]. The fourth paper using the PSQI showed that on two
components of the measure scores were significantly worse in psoriasis subjects than healthy
controls (subjective sleep quality; 1.48±0.17 vs. 1.02±0.13 and habitual sleep efficiency; 0.79
±0.19 vs. 0.32±0.14) [38]. Nevertheless, they did not report data for one component nor did
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they provide global PSQI scores for both groups [38]. Furthermore, one of these studies showed
significantly increased ISI scores in psoriasis patients (11.0±7.0) relative to healthy controls (6.3
±6.0) [23], with psoriasis patients’ mean score at the threshold for clinical insomnia [61].
Four studies found high rates of OSA in psoriasis patients ranging from 36% to as high as
56.3% [27,35,36]. Moreover in a large epidemiological study, psoriasis patients had a signifi-
cantly increased prevalence of sleep disorder diagnosis than non-psoriasis counterparts [57]
and in another, psoriasis patients with a sleep disorder had elevated cardiovascular risk relative
to those without a sleep disorder [56].
Factors associated with sleep disturbance
Sixteen of the 32 reviewed studies reported factors associated with sleep disturbance. Itch,
depression, PsA and pain were the most commonly reported factors associated with sleep
disturbance however others were reported across studies. Itch was reported to occur more
frequently at night [50] and in six studies it was associated with disrupted sleep [25,37,42,44,
50,52]. Itch predicted lower scores on the MOS-SS, indicating worse sleep [42]; increased
scratching was associated with more awakenings during stages 1 and 2 of sleep [37]; and itch
was reported by subjects as causing difficulty initiating and maintaining sleep as well as per-
forming daily activities [44]. Additionally, in one study 65% of participants reported that sleep
ameliorated itch [52].
Table 6. Rates of sleep disturbance found in studies where sleep wasmeasured or quantified within
the sample. Studies where the whole sample had sleep disturbance or where the number of those
experiencing sleep disturbance are not included in this table.
Rates of sleep
disruption (%)
Measures used to assess sleep
Karaca et al. 18/32 (Dx with OSA)
(56.3)
Polysomnography
Papadavid et al. 19/35 (Dx with OSA)
(54.3)
Polysomnography
Buslau &
Bentomane
9/25 (Dx with OSA)
(36)
Polysomnography
Gezer et al. 35/41 (85.4) PSQI
Shutty et al. 81.80% PSQI
Ljosaa et al.
2012
63% GSDS
Sharma et al. 17/30 (56.7) GHQ-H
Ljosaa et al.
2010
74/139 (53.2) BPI (30)
Hu et al. 60/100 (60) Willingness-to-pay (proxy HRQoL measure)
Delﬁno et al. 22/40 (55) Willingness-to-pay (proxy HRQoL measure)
Dufﬁn et al. 208/420 (49.5) Individual question ('In a typical month how many days did
your disease interfere with your sleeping?')
Nyunt et al 91/223 (40.9) Clinical interview
Sanchez-Carazo
et al.
125/1022 (12.2) Medical History
Chiu et al. 2,223/99,628 (2.23) Sleep disorder diagnosis
Tsai et al. 28/51,800 (0.05) Sleep disorder diagnosis
BPI–Brief Pain Inventory, Dx–Diagnosed, GHQ–General Health Questionnaire,
GSDS–General Sleep Disturbance Scale, HRQoL–Health Related Quality of Life,
OSA–Obstructive Sleep Apnea, PSG–Polysomnography, PSQI—Pittsburgh Sleep Quality Index
doi:10.1371/journal.pone.0157843.t006
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The association between itch and sleep was documented further in one study finding the
association between depressive symptoms and itch severity was partially mediated by sleep
quality [40]. In another study daytime sleepiness was associated with depression [28]. Con-
trasting findings were indicated by one study in which itch levels were reported as equivalent
across those with and without sleep disruption, whereas depression was significantly higher in
those who experienced sleep disruption relative to those who did not [51]. This suggests that
depression may have played a greater role in sleep disruption than itch. This is supported by
another study showing that when controlling for depression variables, psoriasis patients are no
more likely to experience poor sleep or have greater insomnia symptoms than controls [23],
and another study showing that while PSQI scores were higher in psoriasis subjects, there were
no differences in psychiatric symptoms relative to controls [38].
Pain appears to contribute to poorer sleep, and in one study over 85% of those reporting
increased pain specified sleep as the most disrupted function [47]. Another study showed that
sleep disturbance mediated the relationship between pain and reduced HRQoL [41]. Four stud-
ies showed associations between PsA and sleep [25,28,39,60]. PsA and generalized pain was
associated with reduced PSQI scores relative to healthy controls [39], increased want for
improved sleep [59] and predicted sleep disturbance [25]. Additionally sleep disturbance was
associated with anxiety, enthesitis, levels of C-reactive protein and erythrocyte sedimentation
rate [39].
Sleep disturbance was consistently associated with reduced QOL [28,47,54,58]. Moreover,
in four treatment studies using biologics, improvements were observed in sleep quality, distur-
bance, daytime sleepiness and adequacy [26,41,43,46] suggesting that improvements in psoria-
sis disease processes may lead to concomitant improvements in sleep. Furthermore in a
longitudinal cohort study sleep showed the greatest improvement from baseline to follow-up
across varied psoriasis therapies (topicals and systemic) relative to other items on the Chil-
dren’s Dermatology Life Quality Index [48].
Discussion
Key findings from the review
This systematic review examined the evidence for sleep disturbance in psoriasis and the mea-
sures and methodology used to assess sleep. The majority of studies showed sleep problems
were associated with itch, low mood and pain. Itch appears to be associated with increased
sleep fragmentation, disturbance and reduced quality of sleep. These findings are consistent
with research in other pruritic conditions [62–64]. Low mood and pain were also implicated in
poor sleep as previously shown in both healthy individuals and other illness populations [65,
66]. It is likely that mood, pain and itch interact disturb sleep; although the nature of this inter-
action requires examination within the context of purposively-designed studies.
Prevalence rates varied substantially and while studies were of fair-to-good quality, many
demonstrated a number of methodological and statistical shortcomings. In particular, the lack
of validated measures of sleep, coupled with limited theoretical work-up may have accounted
for the variation in rates of sleep disturbance across studies. Nevertheless, prevalence clustered
around the 50–60% mark; higher than current estimations of sleep pathology in the general
population [67]. Additionally, rates of OSA appear to be higher in psoriasis (36–56.3%) relative
to the general population (3–7%)[68]. Although the reasons for this are unclear; OSA is multi-
faceted, involving both inflammatory pathways and lifestyle factors including high BMI and
physical inactivity [69]. OSA can have a significant impact on health and contribute to cardio-
vascular disease risk [70], which is already elevated in psoriasis [4]. Further research should
identify mechanisms underpinning the link between OSA and psoriasis.
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Lack of detailed assessments and incomplete data reporting have impeded further conclusions
and provide a somewhat superficial picture of the true problem. For instance, studies using the
PSQI often failed to report full data for the measure (sleep quality, sleep latency, sleep duration,
habitual sleep efficiency, sleep disturbance, use of sleeping medication and daytime dysfunction).
Providing these data would facilitate a more thorough and itemised understanding of sleep quality.
Moreover, despite the ‘gold standard’ PSG being used in five studies, it provides limited
information about the range of factors that may impact upon sleep [71, 72]. Comprehensive
assessment of sleep involves the integration of objective and subjective measures, profiling of
sleep-wake patterning over time, and the assessment of factors that may contribute to night-to-
night variation in sleep quantity and quality [71,72]. We found no studies in this review that
conformed to these standards and neither actigraphy nor sleep diaries have been applied in
psoriasis populations. These data would support a more nuanced understanding of sleep dis-
ruption in psoriasis and help to design appropriate interventions [71,72].
Limitations
This review only included studies published in English and those that have undergone peer
review. Therefore, it is possible that some relevant findings may have been missed. Further, due
to the subjective nature of the quality scoring, there is greater opportunity for personal bias to
influence scores. However we attempted to minimize this risk by the authors scoring papers inde-
pendently and there was close to 100% agreement in paper scores following independent scoring.
Concluding remarks: Recommendations for future research
There is a need to systematically and consistently examine sleep in psoriasis populations,
employing comprehensive and validated measures of sleep in specifically designed studies.
Accurate prevalence rates of sleep disturbance must first be established; from here prospective
studies can explore the relationship between sleep and psoriasis, focusing on potential precipi-
tating and perpetuating factors that may drive and maintain poor sleep, (candidate targets:
itch, mood, pain and OSA). Work should also explore sleep-wake variability in this population
and assess any concomitant consequences on daytime functioning.
Obtaining a comprehensive understanding of sleep in psoriasis is of importance due to the
implications of sleep disruption for health. Sleep disturbance may result in disruptions to
immune and sympathetic nervous system functioning possibly leading to the maintenance
and/or exacerbation of psoriasis, conferring risk for adverse psychological and medical out-
comes. This has been suggested in a recent study which found that the presence of a sleep dis-
order alongside psoriasis confers increased risk for CVDmorbidity [56].
The potential role of inflammation in the relationship between poor sleep and psoriasis has
also been suggested. Four studies included in this review [26,41,43,46] showed improvements
but not a mitigation of sleep problems following the administration of biologic medication.
This suggests that reductions in systemic inflammation may confer sleep improvement possi-
bly through a reduction in itch and associated skin discomfort. Further research is required to
examine mediating pathways and treatment mechanisms in greater detail.
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